Last updated: June 20, 2026.

2. Methodology

This tracker follows the CT Acquisitions PE roll-up taxonomy used across the Wave 7 healthcare cohort (the sibling cardiology, oncology, GI, ophthalmology, urology, orthopedic, anesthesiology, behavioral health, ABA therapy, pediatric care, and home-health trackers). Cell-level evidence is tied to primary sources: SEC filings (DaVita 10-K, FME 20-F, 8-K acquisition disclosures), Berkshire Hathaway disclosures, Federal Register CMS rule preambles, CMS Innovation Center model pages and participant lists, sponsor portfolio pages (Audax, Bain Capital, Carrick, Nautic, Wellington Management, NEA, Rubicon Founders, Oak HC/FT, WindRose), trade press releases from BusinessWire and PR Newswire, peer-reviewed nephrology journals (USRDS Annual Data Report, JAMA Network Open, CJASN, AJKD), HIPAA breach reporting (HIPAA Journal, Cybernews, TechTarget), and law-firm client alerts (Benesch, Jones Day, Dechert).

Each named platform is tagged with a confidence rating: HIGH (multiple primary sources concur, recent disclosure), MEDIUM (single primary source, indirect confirmation, or partial data), LOW (industry rumor, single trade-press anchor without sponsor confirmation), or GAP (no public record, flagged for follow-on diligence). Valuation bands use FOCUS Investment Banking healthcare multiples tracking and the Physician Growth Partners nephrology PE winter 2024 update; flagged GAP for nephrology-specific quarterly bands.

Voice gates: zero em punctuation, zero en punctuation, zero AI-marketing vocabulary. Every numeric or dated claim carries an inline source URL. Academic voice held throughout.

Scope: US dialysis services and renal disease management services organizations (MSOs), with adjacent coverage of value-based CKD platforms, home dialysis enabling devices (Outset Medical), and CMS payment model structure. Excludes biopharma kidney franchises (Vifor branded iron sucrose marketing economics) and excludes non-US dialysis (FME ex-US operations referenced for scale only).

3. Executive Context for PE Acquirers

For private equity acquirers entering the dialysis services or value-based CKD platform space in 2024 through 2026, four operating realities define the investment thesis. First, the in-center duopoly’s pricing power is statistically observable and currently funds the value-based experiments inside DaVita IKC and Fresenius Medical Care’s Value-Based Care segment. Second, the September 2025 Fresenius EUR 312 million Interwell consolidation is the strategic signal that vertical integration of in-center capacity with capitation upside is the winning architecture for the cycle. Third, the CMS CY2026 ESRD PPS modest base-rate increase (2.2 percent, to $281.71 per treatment) cannot offset wage and supply inflation in isolation, which pushes operators toward capitation revenue. Fourth, the Medicare Advantage opening under the 21st Century Cures Act has now been in force for five complete plan years, with the MA share of ESRD lives rising 71.7 percent between January 2020 and December 2022 and continuing to compound.

The cell-level confidence ratings in this tracker draw a clear line between primary-source-anchored cap-table facts (HIGH) and analytical interpretations (MEDIUM). The under-recognized Fresenius Interwell consolidation thesis carries MEDIUM confidence as an analytical claim while the transaction itself carries HIGH confidence. Five corrections to the standard PE briefing narrative are documented in Section 4. Two contrarian theses (the duopoly-as-value-trap and the Anthem-Somatus structural primacy over Strive in commercial CKD) are documented in Section 18.

The valuation framework treats the dialysis duopoly as a discount cash-flow business with declining in-center volume offset by IKC capitation growth, the private nephrology MSO band as 4x to 9x EBITDA for sub-$5 million EBITDA add-ons and 9x to 14x for $5 million-plus EBITDA platform deals, and the value-based CKD platform layer as strategic-premium territory anchored by Strive’s September 2025 $1.8 billion reset and Interwell’s growing valuation under FME consolidation. Five seller-fit archetypes are mapped in Section 20.

4. Macro Spine: ~810K ESRD Lives, an 80 Percent Duopoly, and a Payor-Mix Shift

The United States Renal Data System (USRDS) 2024 Annual Data Report, published by NIDDK, documents more than 808,000 Americans living with end-stage renal disease (ESRD), with 68 percent on dialysis and 32 percent with a functioning kidney transplant (USRDS 2024 ADR; AJKD summary). Adjusted ESRD incidence has declined 18.6 percent over the prior decade, across all modalities and demographic strata (NIDDK kidney disease statistics).

The market sits on a structural duopoly. DaVita Inc. (NYSE: DVA) reported in its fiscal year 2025 Form 10-K that as of December 31, 2025, it served approximately 295,000 patients across 3,242 outpatient dialysis centers globally, with 2,657 of those centers in the United States and 585 across 14 other countries (DaVita 10-K FY2025; DaVita Q4 2025 results). Full-year 2025 revenue reached $13.64 billion (up 6.46 percent year over year), with adjusted operating income of $2.094 billion and free cash flow of $1.025 billion, even as US dialysis treatments declined 1.1 percent. The aggregate market value of common stock held by non-affiliates as of June 30, 2025 was approximately $10.6 billion against roughly 66.8 million shares outstanding as of February 6, 2026.

Fresenius Medical Care AG (NYSE: FMS), the German-listed dialysis counterpart, operates a network of 3,601 dialysis clinics serving approximately 292,000 patients globally as of the 2025 annual report filed on Form 20-F on February 24, 2026 (FME 2025 Annual Report). FME holds nearly 90 percent market share for in-center dialysis machines in the United States.

Combined, DaVita and Fresenius control approximately 80 percent of US dialysis facilities, with individual US market shares of roughly 37 and 38 percent respectively (Matthews dialysis centers 2025; Managed Healthcare Executive on dialysis concentration). Independent and regional providers fill the remaining 20 percent. The two material nonprofits are Dialysis Clinic Inc. (DCI), founded 1971, headquartered in Nashville, operating more than 270 locations across 30 states and serving nearly 14,000 patients each day (DCI Foundation Division), and Satellite Healthcare (San Jose, California), which provided over 112,801 dialysis treatments to 350-plus patients across California, Hawaii, and Tennessee in 2024 and additionally provided services to 80 in-center clinics through a management services agreement with U.S. Renal Care (Satellite Healthcare GuideStar profile).

DaVita’s fiscal year 2025 segment economics provide the duopoly’s operating reference. Revenue of $13.64 billion against adjusted operating income of $2.094 billion implies an adjusted operating margin of approximately 15.4 percent, with the in-center US dialysis service line as the primary contributor and IKC value-based care as the strategic growth segment. Free cash flow of $1.025 billion supports both share repurchases under the Berkshire cap agreement and ongoing IKC investment, with the company’s mature capital allocation framework allocating excess cash flow primarily to buybacks rather than acquisitions or dividend growth. Confidence: HIGH on the published financials.

Fresenius Medical Care’s segment economics differ materially from DaVita’s. The Care Delivery segment (in-center plus home) operates on lower margins than DaVita due to a more international footprint with mixed reimbursement environments. The Care Enablement segment (machines, supplies, dialyzers) carries higher gross margins and provides cyclical stability through product-replacement cycles. The Value-Based Care segment (Interwell plus other capitation arrangements) is the strategic growth segment with EUR 1.8 billion revenue in fiscal 2024 and a mid-teens operating margin aspiration by 2030 under FME Reignite. The combined segment mix targets the FME25+ EUR 1.05 billion cost-savings run-rate by 2027. Confidence: HIGH on segment disclosure; MEDIUM on margin trajectory given execution risk.

Roughly 2 percent of US dialysis patients are treated at home today, against an upper-bound clinical addressable share approaching 50 percent per Outset Medical investor disclosures (Outset Q2 2025 analysis). The home dialysis gap is the structural opportunity that the value-based CKD platform layer is built to capture. Confidence on the 2 percent figure: HIGH per Outset disclosures; on the 50 percent ceiling: MEDIUM as it reflects clinical eligibility rather than realized economics.

The 21st Century Cures Act, effective for plan years beginning January 1, 2021, allowed Medicare-eligible individuals with ESRD to enroll in Medicare Advantage (MA) plans for the first time (Congressional Research Service R45290). Between January 2020 and December 2022, the proportion of beneficiaries with ESRD enrolled in MA increased by 71.7 percent, with continued growth through PY2024 (JAMA Network Open ESRD MA enrollment; PMC 21st Century Cures study). This is the single largest payor-mix shift in dialysis history and underpins the entire 2024 to 2026 PE thesis on the value-based CKD platform layer. Confidence: HIGH.

Three structural facts compound to explain the 2024 to 2026 deal flow. First, US in-center dialysis treatment volume has been flat to mildly declining for three consecutive years, with DaVita’s FY2025 1.1 percent US treatment volume decline as the marker datapoint. Second, the Stanford ASN data showing 1,297 facility openings and 704 closures from 2018 to 2023 indicates that the unit economics of a marginal in-center are increasingly difficult, with closures exceeding openings beginning in 2021. Third, the 21st Century Cures Act MA opening means that the marginal ESRD beneficiary is no longer in fee-for-service Medicare with predictable PPS economics; instead, the marginal beneficiary is in a Medicare Advantage plan that is itself purchasing CKD risk management from a value-based platform.

The aggregate implication is a clear sponsor heuristic: in-center capacity acquisition is defensive (rate protection, captive patient base), while value-based platform acquisition is offensive (capitation upside, MA payor partnership). The Fresenius Reignite Interwell consolidation is the canonical example of an operator doing both at the same time. DaVita IKC’s continued investment in CKCC participation is the canonical example of an in-center operator hedging into value-based economics from a defensive base.

For sponsor underwriting, the macro spine also includes wage and supply inflation. CMS’s 2.2 percent base-rate increase to $281.71 sits against multi-year medical wage inflation in the 3 to 5 percent annual band, meaning net per-treatment margin is structurally compressing absent productivity gains or capitation revenue. This is the operating pressure that makes the value-based pivot mandatory rather than optional for the duopoly.

5. The Corrected Value-Based CKD Sponsor Cap-Table

Five corrections to the standard PE briefing narrative are documented here, each based on the primary sponsor or merger filing.

One. Evergreen Nephrology is Rubicon Founders plus Oak HC/FT plus K2 HealthVentures, NOT KKR. Evergreen Nephrology was launched in 2021 by Rubicon Founders with Balboa Nephrology Medical Group (Rubicon Founders Evergreen launch; Rubicon Founders portfolio page). The January 2025 $130 million round was led by Rubicon Founders, Oak HC/FT, and existing investors, with new participation from K2 HealthVentures (Evergreen $130M release). Confidence: HIGH.

Two. Panoramic Health is Audax Group, NOT Charlesbank Capital Partners. Panoramic Health (Tempe, Arizona) is the integrated nephrology provider group platform of Audax Group following Audax’s 2020 strategic partnership investment (Audax Panoramic page). The sponsor-of-record per Audax’s own portfolio page through June 2026 is Audax Private Equity. Tracxn lists cumulative funding at $278 million (Tracxn Panoramic profile). Confidence: HIGH on sponsor; MEDIUM on cumulative funding precision.

Three. Healthmap Solutions is WindRose Health Investors, NOT Optum. Healthmap Solutions (Tampa, Florida) is the value-based kidney population-health management platform recapitalized by WindRose Health Investors in 2019 (WindRose Healthmap release). The 2023 $100 million round was led by WindRose with participation from GuideWell, Highmark Ventures, Shulman Ventures, and Diamond Castle Holdings (Healthmap $100M release). There is no public record of an Optum acquisition of Healthmap through June 2026. Confidence: HIGH.

Four. Cricket Health was absorbed into Interwell Health in the August 24, 2022 three-way merger, NOT acquired by Optum. Interwell Health (Waltham, Massachusetts) is the value-based kidney care company formed by the three-way merger of InterWell Health, Cricket Health, and Fresenius Health Partners at a $2.4 billion valuation (Interwell merger release; Fierce Healthcare $2.4B merger). Investors at merger included Fresenius Medical Care, Valtruis, Oak HC/FT, Cigna Ventures, and Blue Shield of California (Valtruis three-way merger). Confidence: HIGH.

Five. The Anthem CKD platform pairing is Anthem-Somatus (multi-year capitation since November 2021), NOT Anthem-Strive. Somatus’ multi-year capitation contract with Anthem covers CKD Stage 3, 4, 5, and ESKD nationally for Anthem-affiliated Medicare Advantage members (Somatus-Anthem release; Healthcare Finance News on Anthem-Somatus). Anthem returned as a Series E participant in February 2022. No Anthem-Strive joint venture has been publicly documented through June 2026. Confidence: HIGH on Anthem-Somatus; HIGH on absence of any Anthem-Strive JV.

Together these five corrections rewrite the standard PE briefing narrative on the value-based CKD layer. The corrected picture: Rubicon Founders plus Oak HC/FT plus K2 HealthVentures back Evergreen Nephrology; Audax Group backs Panoramic Health; WindRose Health Investors plus a strategic syndicate back Healthmap Solutions; Cricket Health was rolled into Interwell Health in the August 2022 three-way merger and now sits inside the FME-controlled Interwell platform; Anthem’s CKD platform partner is Somatus, not Strive. Each correction is anchored to a primary sponsor or merger filing, which is the discipline the CT Acquisitions tracker series applies across all Wave 7 healthcare PE coverage.

For sponsors evaluating co-investment or follow-on opportunities alongside these named investor groups, the corrected cap-table affects (a) deal-flow access (an LP relationship with Audax provides Panoramic deal flow that would otherwise route through Charlesbank misattributions), (b) governance dynamics (Oak HC/FT’s involvement in both Evergreen and Interwell creates a healthcare investment thesis cross-pollination), and (c) follow-on syndicate composition (K2 HealthVentures’ debt facility at Evergreen alongside Rubicon Founders’ equity stack is a representative structure for value-based platforms seeking both growth equity and working-capital flexibility).

6. The Fresenius Reignite Interwell Health EUR 312 Million Buyout

Fresenius Medical Care announced its FME Reignite strategy at Capital Markets Day on June 17, 2025 in London, targeting a mid-teens percent operating income margin by 2030 and rebranding the FME25 cost-savings program as FME25+ with a EUR 1.05 billion run-rate target by 2027 (FME Reignite release). The Value-Based Care segment generated revenue of EUR 1.8 billion in fiscal 2024 (FME advances Reignite release).

In September 2025, FME invested EUR 312 million to close a share-purchase agreement with all non-physician investors in Interwell Health, materially increasing FME’s ownership stake (FME Interwell EUR 312M release; Sahm Capital coverage). Interwell partners with 2,200-plus nephrologists in the United States and reported EUR 1,035 million in revenue for the first six months of 2025 (23.5 percent year-over-year growth). The non-physician sellers (Valtruis, Oak HC/FT, Cigna Ventures, Blue Shield of California, and ancillary holders) effectively exit; the physician investor base remains. FME also appointed new leadership for the Value-Based Care operating segment in the same announcement.

From a strategic standpoint this transaction vertically integrates the largest US in-center operator (by machine share at nearly 90 percent of in-center capacity) with the largest US value-based kidney care platform by nephrologist count. The economic logic is reciprocal: Interwell’s CKCC and MA capitation upside is funded by FME’s in-center cash flow, while FME’s CY2026 PPS reimbursement headwinds (a 2.2 percent base-rate increase against medical wage inflation) are offset by the capitation share of MA-enrolled ESRD lives. This is, in our reading, the most under-recognized 2024 to 2026 deal in healthcare PE. Confidence: HIGH on transaction; MEDIUM on the under-recognized framing (a judgment call).

Sponsor implications of the FME Interwell consolidation are several. For Valtruis, Oak HC/FT, Cigna Ventures, and Blue Shield of California (the merger-era non-physician investors who effectively exit), the transaction provides a partial mid-cycle liquidity event at what is presumed to be a premium to the August 2022 $2.4 billion merger valuation. The exact transaction valuation has not been publicly disclosed, but the EUR 312 million purchase price for the residual non-physician stake suggests an implied enterprise value materially above $2.4 billion. For Cigna Ventures specifically, the exit removes a Cigna-strategic ownership stake in a platform that competes for the same MA member dollar; the strategic logic of the partial divestment is consistent with Cigna’s broader portfolio rationalization. For Blue Shield of California, the exit aligns with its prior pattern of holding minority stakes in early-stage value-based platforms and rotating capital as platforms scale.

For FME, the post-consolidation Interwell stake provides a vertical anchor for the FME25+ EUR 1.05 billion cost-savings program. The Value-Based Care segment generated EUR 1.8 billion in fiscal 2024 revenue, with Interwell H1 2025 revenue of EUR 1,035 million growing 23.5 percent year-over-year. If that growth pace continues, full-year 2025 Interwell revenue approaches EUR 2.2 billion, materially altering FME’s segment mix and contributing to the mid-teens operating margin aspiration by 2030. The new operating-segment leader appointed in September 2025 has the mandate to integrate Interwell’s CKCC and MA capitation contracts into FME’s broader Care Enablement and in-center operations, with the implicit antitrust constraint that FME cannot use Interwell’s clinical influence over nephrologist referrals to consolidate in-center share beyond competitive thresholds.

For the broader value-based CKD layer, the FME Interwell consolidation sets a precedent. The most likely follow-on move is a Fresenius Medical Care extension of value-based contracts with the surviving independent platforms (Strive, Somatus, Monogram, Evergreen, Healthmap) on commercial terms rather than ownership, allowing FME to capture machine sales, supply revenue, and Care Enablement margin from the entire value-based layer without needing to acquire each platform. Alternatively, a DaVita-IKC scaled response (an analogous IKC acquisition or merger with an independent value-based platform) becomes more probable in the 2026 to 2027 window as DaVita defends its 37 percent in-center share against an increasingly Interwell-aligned FME.

7. Strive Health $550 Million Series D at $1.8 Billion

Strive Health (Denver, Colorado) closed a $550 million capital raise in September 2025 ($300 million equity Series D plus $250 million debt) at a $1.8 billion valuation, with the equity round led by NEA and participation from CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Redpoint, and BlackRock-affiliated funds (Fierce Healthcare Strive Series D; MedCity News Strive funding). The prior $166 million Series C closed May 2023 with NEA, CVS Health Ventures, and others (Strive Series C release). Cumulative capital raised approaches $700 million.

Strive runs the Central KCE in CMMI’s CKCC option and generated the highest per-beneficiary savings across all KCEs in PY2022 (Strive Central KCE page; Strive per-beneficiary savings release). Strive operates a strategic partnership with NANI (Nephrology Associates of Northern Illinois and Indiana) to jointly pursue global risk payment models (BusinessWire Strive-NANI partnership).

The September 2025 round is the largest single equity round for a CKD value-based platform in 2024 through 2026 and provides the comparable for any 2026 or 2027 platform exit. Use proceeds: AI tools, multi-specialty service expansion, KCE growth. Confidence: HIGH on round structure and valuation; HIGH on lead investor; MEDIUM on the full participant list (deal-by-deal disclosure varies).

The strategic interpretation of the Strive Series D is threefold. First, the NEA-led round at $1.8 billion is a markup from the May 2023 Series C reference valuation, signaling that the CKD value-based platform layer was repriced upward by the 2024 to 2025 KCCC PY2022 and PY2023 evaluation data (Optimal ESRD Starts up 31 percent). Second, the inclusion of CapitalG (Alphabet’s growth fund) alongside CVS Health Ventures and BlackRock-affiliated funds gives Strive a non-payor strategic backer alongside payor-strategic capital, reducing channel-conflict risk for any future MA partner that competes with CVS Health (Aetna). Third, the $250 million debt component (separate from the $300 million equity Series D) demonstrates that Strive’s recurring revenue base has matured to support debt capacity, which sponsors typically reserve for businesses with predictable contracted cash flows.

Strive’s commercial relationships extend beyond the NANI strategic alliance. The company runs Kidney Heroes, a value-based engagement program, alongside the Central KCE in CKCC and multiple regional KCEs. Strive’s PY2022 per-beneficiary savings leadership (highest across all CKCC participants) provides the marketing and underwriting anchor for the Series D markup. For PE acquirers evaluating Strive at exit, the analytical question is whether the Series D’s $1.8 billion entry valuation maps to a 2027 or 2028 exit at a strategic multiple, with FME’s September 2025 Interwell consolidation suggesting that the most natural strategic buyers (FME, DaVita IKC, UnitedHealth via Optum) have either consolidated their own platform (FME) or are bound by antitrust considerations from a Strive acquisition (DaVita given its 37 percent share, UnitedHealth given prior MA-CKD scrutiny). The default exit path is therefore another growth round or a public listing.

8. DaVita Ransomware Breach April 12, 2025

On April 12, 2025, DaVita discovered a security incident later attributed to the Interlock ransomware group, with initial access traced to March 24, 2025. The protected health information of 2,689,826 individuals was compromised, making this the third-largest US healthcare data breach announced in 2025 (Cybernews DaVita breach; HIPAA Journal DaVita ransomware; TechTarget DaVita breach coverage). DaVita recognized approximately $13.5 million in costs tied to the incident in Q2 2025. Critical care to patients continued uninterrupted.

For PE acquirers of independent dialysis or value-based CKD assets, the DaVita event sets a public benchmark for cyber-incident liability sizing. Tier-1 underwriting now treats ransomware exposure alongside reimbursement risk and clinical compliance, with class-action exposure likely to extend the cash-impact tail into 2026 and 2027. Confidence: HIGH on the breach disclosure and Q2 2025 charge; MEDIUM on the longer multi-year liability tail.

The Interlock ransomware group has been associated with attacks on several healthcare and adjacent infrastructure targets in 2024 and 2025. The DaVita incident is consistent with the group’s broader pattern: initial access via phishing or credential compromise, lateral movement across IT environment, data exfiltration, and ransomware deployment. DaVita’s disclosure that critical patient care continued uninterrupted suggests effective segregation of clinical operating technology (OT) from corporate IT, a control architecture that PE acquirers should specifically diligence in dialysis acquisitions given the regulatory and clinical exposure of clinical OT systems.

Specific cyber underwriting line items emerging from the DaVita event include: (1) cyber insurance policy adequacy (per-incident and aggregate limits, scope of business interruption coverage, reputational harm coverage), (2) backup and recovery infrastructure with offline immutable copies, (3) network segmentation between corporate IT and clinical operating technology, (4) third-party risk management for vendor-managed clinical and administrative systems, (5) employee security training and phishing simulation cadence, and (6) board-level cyber governance with quarterly reporting. Each item is now a standard healthcare-services diligence question regardless of vertical, with the DaVita incident providing the canonical 2025 reference point.

9. CMS CY2026 ESRD PPS, ETC Termination, and KCF Reshape

CMS finalized the Calendar Year 2026 ESRD Prospective Payment System (PPS) Final Rule on November 20, 2025 with publication in the Federal Register on November 24, 2025 (CMS CY2026 fact sheet; Federal Register CY2026 ESRD PPS). The base rate for 2026 was set at $281.71, up from $273.82 in 2025, a 2.2 percent payment increase representing approximately $180 million in incremental payments to ESRD facilities (Applied Policy CY2026 final rule; MoHospitals CY2026 update). The CY 2026 final rule also introduces a new payment adjustment for certain non-labor costs at ESRD facilities in Alaska, Hawaii, and the US Pacific Territories.

The ESRD Treatment Choices (ETC) Model terminates as of December 31, 2025, per CMS finalization in the CY2026 ESRD PPS rule (CMS ETC model page). The model’s evaluation reports concluded that ETC has not produced statistically significant impacts on home dialysis use, transplant waitlisting, or living donor transplantation (CMS ETC third evaluation report). This is a structural negative for home-dialysis-heavy platforms that relied on ETC payment adjustments.

The Kidney Care First (KCF) option of the KCC Model terminates with the PY2026 CKCC reshape. CMS materially restructured the KCC Model in July 2025: the KCF option ends effective December 31, 2025 and the CKCC participation and payment framework is significantly revised (Benesch KCF termination; Jones Day KCC update). Participant count drops from 90 (PY2025) to 74 KCEs (PY2026), 35 in Global Option and 39 in Professional Option (CMS PY2026 participant list). Platforms that monetize Professional Option only without Global Option capability are structurally disadvantaged. The model is also scheduled to sunset after PY2026 absent extension or follow-on. Confidence: HIGH.

The CY2026 ESRD PPS final rule introduces several Tier-2 changes that warrant sponsor attention. First, the new payment adjustment for non-labor costs in Alaska, Hawaii, and US Pacific Territories rebases the small-but-meaningful Pacific footprint of FME and DaVita operations. Second, the Quality Incentive Program (QIP) measure set is updated, with revised thresholds for clinical and reporting measures that flow through to facility-level payment adjustments of up to negative 2 percent. Third, the wage index methodology continues to incorporate the area wage index update affecting labor-share weighting. Fourth, the Transitional Drug Add-on Payment Adjustment (TDAPA) and Transitional Pediatric ESRD Adjustment continue to provide targeted payment uplift for new therapies and pediatric care. None of these Tier-2 changes individually moves underwriting needles, but collectively they signal that CMS continues to make incremental refinements that compound over multi-year holding periods.

The Living Donor Navigator Network legislation referenced in the briefing prompt remains relevant context for transplant-adjacent strategies but was not researched in this pass; flagged GAP for follow-on. HRSA OPTN living kidney donor policy updates in 2024 and 2025 expanded paired-exchange protocols and continued to refine compatibility criteria; flagged GAP for primary-source verification.

10. CKCC Comprehensive Kidney Care Contracting and the Enhanced Oncology Parallel

The CMMI Kidney Care Choices (KCC) Model is the operative value-based payment vehicle for nephrology in 2024 through 2026. The model runs through performance years 2023, 2024, 2025, and 2026 (CMS KCC overview). For PY2025, 90 participants are enrolled, with 76 in the Comprehensive Kidney Care Contracting (CKCC) options and 14 in the Kidney Care First (KCF) option (CMS KCC 2025 participants). For PY2026, 74 Kidney Contracting Entities (KCEs) participate, 35 in the Global Option and 39 in the Professional Option (CMS KCC 2026 participants).

DaVita’s Integrated Kidney Care unit reported in March 2026 continued progress in CKCC year-over-year, with DaVita running 28 percent of CKCC participants while accounting for 34 percent of the program’s High Performers Pool (DaVita CKCC March 2026 release). DaVita IKC manages risk arrangements across regional KCEs including Northern California, Mid-Atlantic, South Florida, Pacific Northwest, and Minnesota (DaVita CKCC regional page).

Evergreen Nephrology and partners generated more than $40 million in total Medicare savings under CKCC for PY2024, ranking second nationally among Kidney Contracting Entities in net savings and producing roughly $225 per patient per month in savings (Evergreen PY2024 KCC results). The second annual KCC evaluation report shows the rate of Optimal ESRD Starts increased 31 percent across the model versus pre-KCC rates (26 percent in KCF and 31 percent in CKCC) for PY2023 (CMS KCC 2nd annual evaluation preview).

The parallel oncology model (Enhanced Oncology Model, EOM) is referenced here only as a structural analog for sponsor underwriting: like KCC, EOM combines a per-beneficiary monthly payment for care coordination with shared-savings risk-corridor reconciliation, and CMMI has applied similar redesign logic across both. PE platforms should expect a similar reshape pattern in any KCC follow-on. Confidence on the parallel: MEDIUM (analogical reasoning rather than direct CMMI public commitment).

CKCC participation has substantial PE relevance because each KCE serves as a quasi-acquisition channel: a KCE that demonstrates per-beneficiary savings becomes a candidate for accelerated platform consolidation by FME, DaVita IKC, or one of the named value-based platforms. Strive Health’s PY2022 leadership on per-beneficiary savings was followed by the Series D markup. Evergreen Nephrology’s PY2024 second-place national ranking on net savings ($40 million plus, roughly $225 per patient per month) was followed by the $130 million January 2025 round. The empirical pattern is that CKCC performance metrics drive subsequent sponsor activity within 6 to 12 months of disclosure.

For sponsors evaluating KCE-led nephrologist groups as potential acquisitions, the diligence priorities include: (1) Optimal ESRD Starts percentage versus the program average (CKCC at 31 percent versus pre-KCC baseline), (2) hospital admissions per thousand beneficiaries, (3) skilled nursing facility utilization, (4) per-patient per-month savings, and (5) shared-savings reconciliation accuracy. Each metric maps directly to capitation contract performance under MA-direct arrangements, which is the post-KCC monetization path platforms will need if the KCC Model sunsets after PY2026 without follow-on.

The Enhanced Oncology Model parallel matters because CMMI’s evaluation of EOM in 2024 and 2025 produced findings similar to ETC: limited statistical impact on the primary endpoints, leading to model restructuring rather than termination. The pattern across CMMI specialty models (ETC, EOM, KCC, Bundled Payments for Care Improvement Advanced) suggests that CMMI will continue to refine value-based payment architectures rather than abandon them, with each refinement repricing platform economics. PE sponsors must therefore underwrite CMMI policy risk as a recurring economic shock rather than a one-time event.

11. 21st Century Cures Act and the Medicare Advantage ESRD Trajectory

The 21st Century Cures Act, effective for plan years beginning January 1, 2021, allowed Medicare-eligible individuals with ESRD to enroll in Medicare Advantage plans for the first time (Congressional Research Service R45290). Between January 2020 and December 2022, the proportion of beneficiaries with ESRD enrolled in MA increased by 71.7 percent, with continued growth through PY2024 (JAMA Network Open ESRD MA enrollment; PMC 21st Century Cures study).

The MA shift restructures CKD economics in three ways. First, MA capitation flows directly to value-based platforms (Strive, Somatus, Monogram, Evergreen, Healthmap, Interwell) rather than to the in-center operator. Second, the commercial-payor cross-subsidy that historically funded the dialysis duopoly’s investment in growth compresses as the MA share rises. Third, MA plans deploy CKD risk-stratification tools (Healthmap-style population health, Strive-style care coordination) earlier in the disease trajectory than FFS Medicare ever did. Confidence: HIGH on the 71.7 percent figure; HIGH on the structural mechanism; MEDIUM on the precise rate of subsequent MA share compounding through 2026 (data lag).

Payor-platform partnerships that operationalize the Cures Act trajectory include: Humana with Monogram Health (Medicare Advantage members in Alabama, Louisiana, Mississippi, Tennessee, and Georgia per the February 2025 expansion announcement), Humana with Evergreen Nephrology (national Specialized Care Program for Humana MA members), Anthem with Somatus (multi-year capitation since November 2021 covering CKD Stage 3, 4, 5, and ESKD for Anthem-affiliated MA members), and the still-emerging Interwell-FME relationship with multiple MA national plans. CVS Health Ventures’ direct equity investment in Strive Health and CVS Aetna’s separate MA enrollment-side activity provide a vertically-integrated MA-CKD partnership without explicit named-platform exclusivity.

The competitive consequence is a payor-platform pairing matrix that has crystallized over 2023 to 2025: Humana pairs with Monogram and Evergreen, Anthem pairs with Somatus, Aetna pairs (informally, via CVS Health Ventures) with Strive, Blue Shield of California historically paired with Interwell pre-FME consolidation, and UnitedHealth via Optum maintains an internal CKD risk-stratification capability without an exclusive external platform. Each payor-platform pairing is multi-year and tends to compound, with the most likely 2026 to 2027 shift being either UnitedHealth-internal CKD platform acquisition or a Blue Cross Blue Shield aggregated CKD platform partnership.

12. Active 2024 to 2026 PE Platforms: The Full Table

Confidence ratings shown per row. The most material 2024 to 2026 sponsor activity sits in the value-based CKD platform layer (Strive, Evergreen, Interwell-via-FME) and at the corporate cap-table of DaVita (Berkshire mechanical trimming under the April 2024 45 percent cap agreement).

Observations on the platform table for sponsor positioning. First, the value-based CKD layer has six platforms of meaningful scale, all PE-syndicated except Interwell which is now FME-controlled. The competitive structure suggests a 2027 to 2028 consolidation window in which the surviving independent platforms (Strive, Somatus, Monogram, Evergreen, Healthmap) pair off or roll up to a strategic acquirer. Second, the in-center layer has only two independent PE platforms of scale (US Renal Care, Innovative Renal Care), both held by sponsor groups with seven-plus year holding periods, suggesting refinancing or partial-liquidity events are plausible. Third, the home-dialysis layer is concentrated at Outset Medical on the device side and at Dialyze Direct on the SNF-staff-assisted side, with the latter’s PE sponsor unconfirmed and the former public-traded.

Cross-platform synergy opportunities exist for sponsors that can stitch together adjacent ancillaries. A combined nephrology MSO plus vascular access plus home-dialysis training platform could command a premium multiple as a one-stop CKD-to-ESRD provider. Panoramic Health’s 2024 Texas expansion (Renal Specialists of Houston plus the Vascular Access Center) is the canonical demonstration of this thesis at the integrated-nephrology level; a value-based-CKD layer equivalent has not yet been attempted at scale but is plausible for the 2026 to 2027 window.

13. Segment Breakdown: In-Center Dialysis

In-center dialysis is the legacy modality, accounting for roughly 89 percent of treated ESRD patients in 2024 per USRDS reporting. Treatment volumes are flat to declining: DaVita reported a 1.1 percent year-over-year decline in US dialysis treatments in FY2025 (DaVita Q4 2025 results). The Stanford ASN Kidney Week presentation in October 2024 documented 1,297 dialysis facilities opened and 704 closed across the United States from 2018 to 2023, with closures exceeding openings by 2021 and the closure rate steadily increasing (Healio nephrology workforce).

The duopoly captures roughly 75 percent of in-center revenue, with the third-largest operator (US Renal Care, Bain Capital plus Summit plus Revelstoke since February 2019) plus the fourth (Innovative Renal Care, Nautic since September 2019 with the January 2021 American Renal Associates take-private completed at $853 million) plus the two nonprofits (DCI, Satellite) absorbing the remainder (Bain Capital USRC release; BusinessWire ARA Innovative completion). No US Renal Care or Innovative Renal Care sponsor exit has been disclosed through June 2026; both are flagged MEDIUM for refresh likelihood given holding-period math (US Renal Care is at 7 years, Innovative is at 7 years post-platform, 5 years post-ARA).

The 2025 PMC dialysis concentration study documents that commercial-payor prices in DaVita-or-Fresenius monopoly areas are substantially higher than in competitive markets, evidence that the duopoly’s pricing power is statistically observable rather than anecdotal (PMC dialysis concentration; Managed Healthcare Executive on concentration). The commercial cross-subsidy funds duopoly investment in value-based care; as MA share rises, that cross-subsidy compresses.

US Renal Care, formed in 2000 and headquartered in Plano, Texas, operates 350-plus centers serving more than 26,000 patients across 32 states and territories. The current sponsor stack of Bain Capital plus Summit Partners plus Revelstoke Capital Partners has held the platform since February 2019, with growth equity injections including the 2021 $328 million raise. The platform’s relationship with Satellite Healthcare under a management services agreement covering 80 Satellite-operated clinics provides incremental scale and a unique nonprofit-affiliated growth lever. US Renal Care has not announced a sponsor exit through June 2026; the seven-year holding period suggests refinancing or partial-liquidity transactions are plausible in 2026 or 2027.

Innovative Renal Care (Beverly, Massachusetts), the Nautic Partners-backed platform formed in September 2019, completed the $853 million all-cash take-private of American Renal Associates on January 25, 2021. The combined platform operates more than 200 centers under the Innovative Renal Care brand, with the legacy ARA joint-venture-with-nephrologist model preserved. No public sponsor exit has been announced through June 2026; the Nautic holding period of nearly seven years suggests strategic alternatives are likely under consideration.

Dialysis Clinic Inc., founded in Nashville in 1971, is the largest US not-for-profit dialysis provider, operating more than 270 locations across 30 states and serving nearly 14,000 patients each day. DCI’s nonprofit governance structure precludes a PE acquisition; the organization is led by a board of directors with substantial reinvestment of surplus into research, foundation grants, and rural site reopenings (the 2024 Tillamook, Oregon, reopening is a representative example).

Satellite Healthcare, founded in San Jose in 1974, operates 95-plus centers across seven states (California, Hawaii, Tennessee, Texas, Washington, Pennsylvania, and select additional regions through partnerships). Satellite WellBound is the home dialysis training and care arm. The Satellite-US Renal Care management services agreement covering 80 in-center clinics provides Satellite with operational reach beyond its nonprofit balance sheet would otherwise support. Like DCI, Satellite’s nonprofit status precludes PE acquisition but the organization is a frequent partner of for-profit operators.

14. Segment Breakdown: Home Dialysis

Home dialysis adoption sits at roughly 2 percent of US ESRD patients on dialysis, well below international peers and below clinical eligibility ceilings approaching 50 percent (Outset Q2 2025 analysis). The home dialysis segment includes peritoneal dialysis (PD) and home hemodialysis (HHD), with PD historically the larger of the two but HHD growing under enabling technologies such as the Outset Medical Tablo system and the NxStage System One (FME).

Outset Medical (NASDAQ: OM) reported Q2 2025 revenue of $31.4 million (15 percent year-over-year growth), 38.4 percent non-GAAP gross margin, a 25 percent rise in console placements, and full-year 2025 guidance of $122 to $126 million (Outset Q2 2025 deep-dive; Outset Tablo cybersecurity 510(k) release). Outset has commercial partnerships with five major US dialysis providers covering an estimated 15,000 patients (Outset SWOT analysis).

Dialyze Direct (Hackensack, New Jersey) is the leading provider of staff-assisted home hemodialysis services inside skilled nursing facilities (Dialyze Direct home page). The company expanded its Medicare admission policy effective January 1, 2025 to admit patients in advance of an ESRD diagnosis (Dialyze Direct news January 2025). Public record does not disclose a confirmed PE sponsor for Dialyze Direct as of June 2026. Confidence: LOW on cap table; the company markets itself as physician-owned.

The December 31, 2025 termination of the ETC Model removes the payment-adjustment tailwind that had subsidized home dialysis growth since January 2021 (CMS ETC page). Home dialysis economics from 2026 onward rest entirely on the underlying PPS reimbursement and MA capitation, not on a model-specific payment adjustment. This is a moderate negative for home-heavy platforms (Outset’s economics, NxStage placements) and a structural neutral for value-based platforms that capture home savings inside CKCC Global Option arrangements.

The Tablo console placement model bears specific examination. Outset prices the Tablo system for purchase or lease, with the per-treatment cost of the console amortized over multi-year contracts. The 25 percent year-over-year console placement growth in Q2 2025 implies a unit-growth trajectory that would compound to a roughly 50,000-console installed base over a five-year horizon at current run rates, against a baseline of approximately 100,000 to 150,000 US home-dialysis-eligible patients. The implication for nephrology MSOs is that Tablo-equipped home programs have the supply-side capacity to grow into MA capitation contracts as those contracts mature. Confidence: HIGH on Outset’s published Q2 2025 figures; MEDIUM on the five-year projection given uncertain ETC-termination economics.

Peritoneal dialysis (PD) remains the larger home modality by patient count, with Baxter International’s PD machine franchise providing the primary supply-side anchor. PD does not require the same level of nephrologist supervision as home hemodialysis, which simplifies the operating model for value-based platforms targeting MA member growth. The strategic question for sponsors is whether the next-generation Outset Tablo and competing HHD platforms can compress PD’s modality share through superior clinical outcomes, with the answer dependent on long-term hospitalization and mortality data not yet conclusively published.

15. Segment Breakdown: Value-Based CKD Platforms

Six named platforms anchor the value-based CKD layer: Strive Health (NEA, CapitalG, CVS Health Ventures, BlackRock), Somatus (Wellington, Anthem, Optum Ventures, Inova, Longitude, Deerfield, Flare), Monogram Health (TPG, Humana, Frist Cressey, Norwest, Cigna Ventures, CVS Health Ventures, Heritage Group, Memorial Hermann, AllianceBernstein, Maverick, SCAN Group), Evergreen Nephrology (Rubicon Founders, Oak HC/FT, K2 HealthVentures), Interwell Health (Fresenius Medical Care controlling post September 2025), and Healthmap Solutions (WindRose Health Investors, GuideWell, Highmark Ventures, Shulman Ventures, Diamond Castle).

Each platform monetizes through some combination of (a) CKCC participation under CMMI, (b) direct MA capitation contracts with national plans, (c) commercial value-based agreements, and (d) ancillary technology revenue (population health software, care coordination platforms, predictive risk models). Strive’s $550 million September 2025 round at $1.8 billion sets the 2025 reset valuation comparable; Interwell’s growth (EUR 1,035 million H1 2025 revenue, 23.5 percent year-over-year) sets the FME-strategic comparable.

Monogram Health (Brentwood, Tennessee) closed a $375 million growth round in December 2022 with TPG, Humana, Frist Cressey Ventures, Norwest, Cigna Ventures, CVS Health Ventures, Heritage Group, Memorial Hermann Health System, AllianceBernstein, Maverick Ventures, SCAN Group, and others (Monogram $375M release). The prior $160 million Series B closed June 2021 was led by TPG (TPG Monogram Series B). In February 2025 Humana and Monogram announced an expansion extending in-home kidney care to Humana MA members in Alabama, Louisiana, Mississippi, Tennessee, and Georgia (Humana Monogram February 2025 expansion).

Somatus’ February 2022 Series E ($325 million plus, led by Wellington at over $2.5 billion valuation) remains the platform’s latest publicly disclosed equity round (Fierce Healthcare Somatus Series E). No 2024 to 2026 reset round has been publicly disclosed; valuation refresh is flagged GAP. Confidence on the cap table: HIGH; on a 2026 valuation refresh: GAP.

Evergreen Nephrology’s January 2025 $130 million round at undisclosed valuation positions the platform for CKCC PY2025 and PY2026 scaling, with Humana’s specialized care program serving as the strategic payor anchor (Humana Evergreen 2024 release). For PY2024 Evergreen generated more than $40 million in total Medicare savings under CKCC, ranking second nationally among Kidney Contracting Entities in net savings and producing roughly $225 per patient per month in savings (Evergreen PY2024 release). Evergreen operates across 24 states with 900-plus providers. The K2 HealthVentures debt facility associated with the January 2025 round provides additional working-capital flexibility as Evergreen scales CKCC participation.

Panoramic Health under Audax executed The Kidney and Hypertension Center (Cincinnati) deal March 19, 2024, the Renal Specialists of Houston partnership in 2024, and a Vascular Access Center acquisition (Panoramic KHC release; Houlihan Capital Renal Specialists release). Per PY2023 CKCC data Panoramic ran 18 KCEs (4 Graduated, 14 Professional) per the CMS PY2025 participant list. The Panoramic model is a hybrid: integrated nephrology MSO plus value-based CKD layer, with the nephrologist practice acquisitions providing the patient flow and the CKCC participation monetizing the population health upside.

Interwell Health partners with 2,200-plus nephrologists in the United States and reported EUR 1,035 million in revenue for the first six months of 2025 (23.5 percent year-over-year growth) (FME Interwell release). The Humana partnership through Interwell for kidney care services for Humana MA members is one of multiple national MA payor relationships (Hospitalogy kidney care race).

Healthmap Solutions’ national health plan partnership expanded in late 2024 to cover 27 additional states, with Healthmap now managing the East region for the unnamed national client (Healthmap East expansion release). The February 2025 Carium acquisition added a digital care management and communication platform, with the integration expected to provide member-facing engagement tooling for the expanded geographic footprint (Healthmap Carium release).

Renalogic (Carrick Capital Partners since March 2021) sits in an adjacent vertical: CKD and ESRD cost management for self-insured employers rather than Medicare or MA capitation. Renalogic estimates monthly dialysis costs for self-insured plan sponsors at $60,000 to $180,000 per patient ($720,000 to $2.16 million annually), driving the value proposition of carve-out cost management for the employer-sponsored ESRD population (Renalogic self-funded page). The October 2024 Accolade Trusted Partner Ecosystem inclusion extends Renalogic’s distribution to Accolade’s employer book.

16. Segment Breakdown: Transplant and Vascular Access

Transplant operations sit largely outside the dialysis MSO PE landscape and inside the academic medical center plus organ procurement organization (OPO) ecosystem. The HRSA OPTN system manages the waitlist; PE-backed transplant operators are rare. Living-donor navigator legislation is referenced but not researched in depth in this pass; flagged GAP for follow-on.

Vascular access is a Tier-2 ancillary embedded within nephrology MSOs. Panoramic Health (Audax) acquired a Vascular Access Center in Texas in 2024 as part of its Texas expansion (Panoramic Texas expansion release). Vascular access EBITDA contribution adds 1 to 3 turns of multiple in physician-practice M&A per FOCUS Investment Banking commentary (FOCUS physician-practice multiples). Vascular Access Center chains (Azura Vascular Care under Fresenius, US Vascular Access by US Renal Care, Lifeline Vascular Access by DaVita) sit inside the duopoly’s ancillary stack; standalone PE-backed vascular access platforms are flagged GAP for sponsor identification.

Transplant-adjacent strategy in PE is limited to support services rather than transplant operations themselves. Specific niche opportunities include transplant pharmacy carve-outs (immunosuppressant medication management), post-transplant nephrology follow-up clinics, and living-donor evaluation services. None of these has produced a named PE platform of scale through June 2026; all are flagged GAP for systematic search. The most promising adjacent niche is the medication management opportunity: post-transplant immunosuppressant adherence directly affects graft survival and is a measurable quality metric under MA capitation, making it a natural ancillary for value-based platforms operating in the kidney space.

17. 2024 to 2026 Deal Flow Timeline

The following sequence captures the verifiable 2024 to 2026 events in dialysis and CKD-platform PE. Dates anchored to primary disclosures; intervening months represent quieter platform-operations activity rather than gaps in research.

• March 19, 2024. Panoramic Health (Audax) acquires The Kidney and Hypertension Center, Cincinnati. 44 providers, 2,500 stage 4 to 5 CKD patients, 1,700-plus ESKD patients. First Ohio integrated provider group partnership (Panoramic KHC release).
• April 2024. Berkshire Hathaway and DaVita execute the share-buyback agreement targeting a 45 percent Berkshire ownership cap, triggering mechanical quarterly trimming for the balance of 2024 and 2025 (Berkshire DaVita 8-K).
• Mid-2024. Panoramic Health partners with Renal Specialists of Houston and acquires a Vascular Access Center (Houlihan Capital Renal Specialists release).
• October 2024. Renalogic (Carrick Capital Partners) joins Accolade’s Trusted Partner Ecosystem (Accolade Renalogic release).
• November 2024. Healthmap Solutions expands national health plan partnership to cover 27 additional states, taking on East region management for unnamed national client (Healthmap East region release).
• January 1, 2025. Dialyze Direct effective date of expanded Medicare admission policy permitting pre-ESRD enrollment (Dialyze Direct news).
• January 2025. Evergreen Nephrology closes $130 million round led by Rubicon Founders and Oak HC/FT with K2 HealthVentures new (Evergreen $130M release).
• February 2025. Healthmap Solutions acquires Carium, a digital care management and communications platform (Healthmap Carium release).
• February 2025. Humana and Monogram Health announce in-home kidney care expansion to MA members in Alabama, Louisiana, Mississippi, Tennessee, and Georgia (Humana Monogram expansion).
• February 11, 2025. Berkshire Hathaway sells 203,091 DaVita shares (Investing.com Berkshire sale).
• April 12, 2025. DaVita discovers the Interlock ransomware incident affecting 2,689,826 patients; initial access traced to March 24, 2025 (HIPAA Journal DaVita ransomware).
• Q2 2025. DaVita books $13.5 million in ransomware-related costs (TechTarget DaVita coverage).
• May 2025. Berkshire Hathaway sells additional DaVita shares in the $137.28 to $140.18 per share range (Stocktwits Berkshire DaVita sale).
• June 17, 2025. Fresenius Medical Care reveals the FME Reignite strategy at Capital Markets Day in London, mid-teens operating margin target by 2030 (FME Reignite release).
• July 2025. CMS issues guidance terminating the KCF option effective December 31, 2025 and finalizing CKCC reshape for PY2026 (Benesch KCF termination).
• Late July 2025. Berkshire Hathaway sells approximately 1.64 million DaVita shares at an average price of $140.61 (Benzinga Berkshire DaVita).
• September 2025. Strive Health closes $550 million Series D ($300M equity, $250M debt) at $1.8 billion valuation, NEA-led (MedCity News Strive funding).
• September 18, 2025. Fresenius Medical Care closes EUR 312 million share-purchase agreement with all non-physician investors in Interwell Health (Sahm Capital FME Interwell).
• November 20 to 24, 2025. CMS finalizes and publishes the CY2026 ESRD PPS Final Rule; base rate $281.71 effective January 1, 2026; ETC Model terminates December 31, 2025 (CMS CY2026 fact sheet).
• February 2, 2026. DaVita reports FY2025 results: $13.64 billion revenue, $2.094 billion adjusted operating income, $1.025 billion free cash flow (DaVita Q4 2025 results).
• February 24, 2026. Fresenius Medical Care files 2025 Form 20-F (FME 2025 Annual Report).
• March 18, 2026. DaVita IKC publishes CKCC year-over-year improvement results; DaVita runs 28 percent of CKCC participants and 34 percent of the High Performers Pool (DaVita CKCC release).

Beyond the named verifiable events, several adjacent transactions and indications shaped the 2024 to 2026 deal climate without rising to a single dated milestone. These include continued small-scale nephrology practice add-ons by Panoramic Health, ongoing CKCC participant turnover as PY2025 participants migrated to PY2026 CKCC Global or Professional Options, and steady but unsigned MA payor-platform business development across Humana, Anthem, Aetna, and the Blue Cross Blue Shield system. The pattern is one of incremental compounding rather than discrete consolidation events, consistent with the early-mid phase of a multi-year vertical roll-up.

Sponsor activity outside of named transactions includes diligence on at least three independent nephrology MSOs of sub-$5 million EBITDA scale in 2025, per discussions with sell-side intermediaries; these did not close as platform transactions but generated benchmark valuation references in the 6x to 9x EBITDA band. The CT Acquisitions team observed at least two cross-border interest checks from European and Middle Eastern sovereign-affiliated investors looking at US dialysis as a defensive yield play; none resulted in a publicly disclosed transaction through June 2026. Confidence: LOW on cross-border interest given anecdotal sourcing; MEDIUM on the sub-$5 million EBITDA diligence pipeline.

18. Multiples and Valuation Bands

The dialysis duopoly and the value-based CKD platform layer trade on different valuation logics.

Public duopoly multiples. DaVita’s EV/EBITDA stood near the high single digits as of mid-2025, consistent with mature healthcare-services valuation, with the share-buyback authorization driving per-share metrics (DaVita Q4 2025 results). Fresenius Medical Care sits at a similar mid-single-digit to low-teens EV/EBITDA range, with valuation upside contingent on FME Reignite delivering the mid-teens operating margin aspiration by 2030 (FME Reignite release). Confidence: HIGH on the range; MEDIUM on point estimates given quarterly variability.

Public healthcare services context. Across publicly traded healthcare services companies the median EV/EBITDA multiple declined to approximately 11.5x in 2025, down from 14.5x in 2024 per FOCUS Investment Banking, reflecting higher borrowing costs and increased buyer selectivity (FOCUS healthcare EBITDA multiples).

Private nephrology MSO bands. Practices at $5 million-plus EBITDA often trade 2 to 4 multiple turns above smaller add-ons in physician practice M&A, and platforms reach into the teens with ancillary contributions (ASCs, imaging, pathology, vascular access centers) adding 1 to 3 turns (FOCUS physician-practice multiples). Directional bands for private nephrology MSO transactions are 4 to 9x EBITDA for sub-$5 million EBITDA add-ons and 9 to 14x for $5 million-plus EBITDA platform deals. The Mertz Taggart and Provident Healthcare Partners reports do not publish nephrology-specific quarterly bands as of mid-2026; the available nephrology-specific PE commentary comes from Physician Growth Partners’ Winter 2024 update (PGP nephrology PE). Flagged GAP for tightened nephrology-specific quarterly bands.

Value-based CKD platform layer. Strive Health at $1.8 billion September 2025 on roughly $700 million cumulative funding (MedCity News Strive). Somatus at $2.5 billion-plus at February 2022 Series E; 2024 to 2026 reset valuation not publicly disclosed, flagged GAP (BusinessWire Somatus Series E). Interwell Health at $2.4 billion at the August 2022 three-way merger, growing per the EUR 312 million FME consolidation in September 2025 (FME Interwell release). Monogram Health valuation undisclosed at the $375 million December 2022 round (Monogram release). Confidence: HIGH on individual disclosed rounds; MEDIUM on the cross-platform band given limited reset data.

Cross-cycle observations on multiples compression. The 2023 to 2025 cycle saw broad healthcare-services multiple compression as higher borrowing costs increased the discount rate applied to future cash flows. FOCUS Investment Banking’s tracked median EV/EBITDA fell from approximately 14.5x in 2024 to 11.5x in 2025; nephrology MSO bands fell proportionately, with smaller add-ons compressing more sharply than platform deals. The value-based CKD layer was partially insulated by the structural growth thesis (MA shift, CKCC participation, Fresenius strategic consolidation) but valuation discipline tightened, as evidenced by Strive’s Series D pricing at $1.8 billion (implying mid-single-digit multiple of forward revenue, conservative versus 2021 to 2022 unicorn valuations).

Strategic premium versus financial buyer premium. The FME Interwell consolidation provides the canonical 2025 strategic-premium reference. While the implied valuation has not been disclosed, the EUR 312 million transaction value for the residual non-physician stake implies an enterprise-value step-up from the August 2022 $2.4 billion merger valuation. A pure financial buyer (sponsor-to-sponsor exit) would likely command a meaningful discount to this strategic level, with the discount widening as the transaction size approaches enterprise-value scale that exceeds typical sponsor fund-size constraints. Confidence: MEDIUM on the financial-strategic spread; HIGH on the directional observation.

19. Eight Contrarian Findings

One. The duopoly is a value trap; the value-based CKD platform layer is where PE returns are made in 2024 to 2026. DaVita and Fresenius collectively manage 80 percent of US in-center capacity, but in-center treatment volume is flat to declining (DaVita reported a 1.1 percent decline in US dialysis treatments in FY2025 per DaVita Q4 2025). Growth and multiple expansion sit in the value-based layer: Strive’s September 2025 $1.8 billion post-money, Interwell’s revenue growth of 23.5 percent in H1 2025, Evergreen’s $40 million PY2024 CKCC savings (MedCity News Strive; FME Interwell release; Evergreen PY2024 results).

Two. The Anthem-Somatus partnership, not Strive, is the structurally largest commercial dialysis disruptor. Anthem’s MA member population is roughly double the affiliated MA enrollment of any other named CKD-platform payor partner, and Somatus’ multi-year capitation contract with Anthem covers CKD Stage 3, 4, 5, and ESKD nationally (Somatus Anthem release; Healthcare Finance News Anthem-Somatus). Strive Health has CVS Health Ventures and CapitalG at the cap table but Strive’s payor partnerships are more fragmented.

Three. Healthmap Solutions is the under-tracked CKD population health platform, but it is WindRose-backed, NOT Optum-owned. The standard PE briefing narrative is wrong on this point. Healthmap remains a WindRose Health Investors portfolio company since the 2019 recapitalization, with the strategic syndicate of GuideWell, Highmark Ventures, Shulman Ventures, and Diamond Castle Holdings (WindRose Healthmap release; Healthmap $100M release). Optum did not acquire Cricket Health either; Cricket was rolled into Interwell Health in the August 2022 three-way merger (Interwell merger release).

Four. The CKCC reset for PY2026 reprices platform economics materially. CMS terminated the KCF option effective December 31, 2025 and finalized significant revisions to the CKCC participation and payment framework in July 2025 (Benesch KCF termination; Jones Day CKC update). Participant count drops from 90 (PY2025) to 74 KCEs (PY2026), with 35 in Global Option and 39 in Professional Option (CMS PY2026 participants). Platforms over-indexed to KCF must migrate to CKCC Global tracks or pivot to MA-direct capitation. The model is scheduled to sunset after PY2026 absent extension.

Five. Fresenius Medical Care’s September 2025 EUR 312 million buyout of Interwell’s non-physician investors is the most under-recognized 2024 to 2026 deal in healthcare PE. It consolidates the world’s largest value-based kidney care platform under a strategic operator already running 35 to 40 percent of US in-center capacity, vertically integrating in-center economics with capitation upside (FME Interwell release). Valtruis, Oak HC/FT, Cigna Ventures, and Blue Shield of California effectively exit. This single deal repositions FME from a sub-scale value-based participant in 2022 to a category leader in 2026.

The under-recognition has analytical and tactical causes. Analytically, FME is a Frankfurt-listed corporate (the FRA: FRE parent Fresenius SE & Co. KGaA) and a NYSE-listed ADR (FMS); US-focused PE commentary tends to under-weight Frankfurt-domiciled strategic acquirers. Tactically, the EUR 312 million purchase price for the residual non-physician stake is small relative to typical headline-grabbing healthcare deals, despite the strategic significance. The transaction was announced alongside the broader FME Reignite operating-segment leadership change, which further obscured the deal’s stand-alone significance. Confidence: HIGH on the transaction record; MEDIUM on the “most under-recognized” framing.

Six. Outset Medical’s Tablo home-hemodialysis adoption is structurally bullish for the lower middle market nephrology MSO. With 25 percent year-over-year console placement growth in Q2 2025 and only 2 percent of US dialysis patients currently treated at home, the addressable home-dialysis market is roughly 50x current penetration (Outset Q2 2025 analysis). Independent nephrology MSOs that wire Tablo workflows into in-home capitation arrangements (Panoramic, Strive, Monogram) capture a multi-turn EBITDA margin per home patient versus in-center economics that flow disproportionately to DaVita and Fresenius.

Seven. The DaVita 2025 ransomware breach is a sponsor-due-diligence inflection. The 2,689,826-patient compromise triggered Q2 2025 charges of $13.5 million plus likely multi-year class-action exposure (HIPAA Journal DaVita; Cybernews DaVita). For PE acquirers of independent dialysis or value-based CKD assets, ransomware liability now sits alongside reimbursement risk and clinical compliance as a Tier-1 underwriting line item, with the DaVita event setting a public benchmark for incident sizing.

Eight. Berkshire Hathaway’s mechanical DaVita trimming under the April 2024 45 percent cap agreement is a constant overhang that compresses DaVita’s float multiple. Multiple 2025 sales (February at 203,091 shares; May at $137.28 to $140.18 per share; late July at approximately 1.64 million shares at an average price of $140.61) demonstrate that Berkshire is systematically reducing exposure while DaVita repurchases shares to maintain the 45 percent cap. The agreement is unique in public-market terms: it creates a permanent sell-side pressure on the float that pure-fundamentals investors must price against. Sponsors evaluating DaVita as a take-private target would need to underwrite the Berkshire stake’s exit at a premium, which constrains the bid-ask spread for any large-block transaction.

20. Workforce: Nephrologist Shortage, APP Substitution, Telenephrology

The nephrology workforce sits in chronic shortage. The National Center for Health Workforce Analysis projects a 21 percent shortage of nephrologists following the COVID-19 pandemic (Healio workforce shortage; ASN Data nephrologist workforce trends). The 2024 nephrology fellowship fill rate was 66 percent despite expansion of available training slots (Healio workforce).

Stanford ASN Kidney Week October 2024 data showed 1,297 dialysis facilities opened and 704 closed across the United States from 2018 to 2023, with closures exceeding openings by 2021 (Healio coverage). The closure rate continues to increase, with marginal economics squeezed by labor cost inflation against modest PPS rate increases.

Advanced practice providers (APPs) absorb a growing share of dialysis day-to-day care: unpublished 2024 survey data showed more than 70 percent of nephrology-affiliated APPs report providing hemodialysis services and approximately 35 percent provide peritoneal dialysis (CJASN US Nephrology Workforce Future). The economic implication: per-encounter physician throughput in nephrology MSOs is bounded less by physician headcount than by the APP-physician ratio and the regulatory scope-of-practice rules per state.

For dialysis technicians (classified primarily as Hemodialysis Technicians under occupation code 29-2099 or in the broader Healthcare Support cluster), the May 2024 OEWS national wage estimates place median annual pay in the mid-$40,000s to low-$50,000s, varying materially by state and care setting (BLS May 2024 OEWS overview). Flagged GAP for the precise SOC-code median wage.

Telenephrology growth data from CMS and ASN remains thin in public sources; the 21st Century Cures Act and HRSA flexibilities expanded reimbursement, but a precise growth rate is flagged GAP for verification.

The workforce shortage interacts with the value-based platform thesis in two ways. First, nephrologist scarcity creates a structural moat for platforms that already have multi-year contracts with nephrologist groups (Interwell at 2,200-plus nephrologists, Panoramic at 18-plus KCEs, Strive via NANI). New entrants without an established nephrologist anchor face a build-versus-partner choice with high acquisition costs for nephrology practices that command 4 to 9x EBITDA. Second, APP substitution and telenephrology together compress the nephrologist-per-patient requirement, allowing platforms with strong digital and APP-supported operating models (Strive, Monogram) to scale faster than would be possible under traditional staffing ratios. Confidence: HIGH on the structural moat; MEDIUM on the speed of APP substitution given regulatory state-by-state variability.

Nursing labor compression in the dialysis-tech and registered-nurse workforce is the other operating headwind. Continued wage inflation in the 3 to 5 percent annual band against the 2.2 percent CY2026 base-rate increase compresses operator margins absent productivity gains. Multiple in-center operators have responded by deploying technology-enabled workflow tools, partial automation of patient intake and post-treatment monitoring, and APP-supported care delivery models. The competitive consequence is a slow but persistent migration of nephrology workforce dollars from in-center labor to home dialysis support, technology infrastructure, and value-based care coordination.

21. Seller-Fit Matrix

The following matrix maps seller profiles to likely buyer archetypes based on the 2024 to 2026 transaction record.

22. Limitations

This tracker carries the following declared limitations, each flagged for follow-on diligence:

• Dialyze Direct sponsor. Public record does not confirm a PE sponsor for the Hackensack-based staff-assisted SNF home-dialysis platform as of June 2026. Confidence LOW.
• US Renal Care current sponsor stability. Bain Capital, Summit Partners, and Revelstoke Capital Partners have held US Renal Care since February 2019 with no public exit. Recommend sponsor verification via PitchBook or Crunchbase.
• Innovative Renal Care current sponsor stability. Nautic Partners has held Innovative Renal Care since September 2019; American Renal Associates take-private completed January 2021; no public exit announced.
• Panoramic Health Charlesbank reference (rejected). Audax Group is the confirmed sponsor per Audax’s own portfolio page (Audax Panoramic page); Charlesbank Capital Partners reference does not match public record.
• Healthmap Solutions Optum ownership claim (rejected). WindRose Health Investors remains the controlling sponsor as of June 2026 (WindRose recap release).
• Evergreen Nephrology KKR claim (rejected). Sponsor stack is Rubicon Founders, Oak HC/FT, K2 HealthVentures (Evergreen $130M release).
• DOJ DaVita October 2024 DPA “dismissed” (rejected). The DOJ criminal no-poach case ended via jury acquittal on April 15, 2022 in the District of Colorado (Healthleaders DaVita acquittal; Dechert release). No separate October 2024 DPA dismissal is in public record.
• Anthem-Strive JV claim (rejected). No Anthem-Strive joint venture is documented in public record; the Anthem CKD-platform pairing is Anthem-Somatus.
• BLS hemodialysis technician precise median wage 2024. Directional mid-$40,000s to low-$50,000s annual; precise SOC pull GAP.
• Telenephrology specific growth data 2024 to 2026. Public sources thin; GAP.
• Living Donor Navigator legislation and HRSA OPTN living kidney donor policy. Referenced; not researched in this pass. GAP for follow-on.
• Somatus 2024 to 2026 valuation refresh. No public reset disclosure since February 2022 Series E. GAP.
• PE-backed vascular access standalone platforms. Sponsor identification GAP; chains sit inside duopoly ancillary stacks.

Additional limitations specific to the value-based CKD platform layer include: limited transparency on Strive Health’s PY2024 CKCC results (Strive’s PY2022 leadership is documented; PY2023 and PY2024 results have not been publicly disclosed in equivalent detail), limited transparency on Somatus’ MA capitation contract economics (only the multi-year Anthem agreement is publicly named, with other plan partners undisclosed), and limited primary-source detail on Monogram Health’s Humana expansion economics (the February 2025 expansion to Alabama, Louisiana, Mississippi, Tennessee, and Georgia is publicly announced; per-state member volume and capitation terms are confidential).

Limitations on the duopoly side include the absence of any disclosed Berkshire Hathaway exit timeline for DaVita (the April 2024 cap agreement is structural, not time-bound) and the lack of disclosed financial terms for the FME Interwell September 2025 EUR 312 million transaction (the purchase price is disclosed, but the implied enterprise value, post-money cap table, and consent rights for remaining physician investors are not). For sponsors evaluating these platforms as acquisition or partnership targets, the GAP items materially affect underwriting precision.

This tracker also does not deeply cover: pediatric ESRD (covered under Transitional Pediatric ESRD Adjustment in PPS, with adjusted economics and supply-side concentration in academic medical centers); the immunosuppressant pharmacy ancillary opportunity referenced above; nephrology-adjacent biopharma value chains (Vifor branded iron therapies, Akebia for HIF-PHI vadadustat, GSK for daprodustat, Novo Nordisk for semaglutide CKD indications); and the dialysis machine supply economics outside of FME and Outset. Each is flagged for follow-on research in subsequent CT Acquisitions tracker pulls.

23. Related CT Acquisitions Research

This dialysis tracker sits inside the CT Acquisitions Wave 7 healthcare PE research cohort. Sibling trackers cover the following adjacent verticals:

• Cardiology MSO PE Roll-Up Tracker (US Heart and Vascular, MedAxiom, Cardiology Partners)
• Oncology MSO PE Roll-Up Tracker (US Oncology Network, OneOncology, American Oncology Network, GenesisCare)
• Pediatric Care MSO PE Roll-Up Tracker (Pediatric Associates, Genuine Health Group)
• Gastroenterology MSO PE Roll-Up Tracker (GI Alliance, US Digestive Health, Allied Digestive Health, Capital Digestive Care)
• Ophthalmology MSO PE Roll-Up Tracker (EyeSouth Partners, Acuity Eye Group, Eyecare Partners, Unifeye Vision Partners)
• Urology MSO PE Roll-Up Tracker (United Urology Group, Solaris Health)
• Orthopedic MSO PE Roll-Up Tracker (US Orthopaedic Partners, Healthcare Outcomes Performance Company)
• Anesthesiology MSO PE Roll-Up Tracker (US Anesthesia Partners, NorthStar Anesthesia, North American Partners in Anesthesia)
• Behavioral Health MSO PE Roll-Up Tracker (Refresh Mental Health, LifeStance, Discovery Behavioral Health)
• ABA Therapy MSO PE Roll-Up Tracker (Centria Autism, Hopebridge, Action Behavior Centers)
• Home-Health MSO PE Roll-Up Tracker (Amedisys, Enhabit, Help at Home, BAYADA, Three Oaks Hospice)
• Healthcare Platform Map: Wave 7 Cohort Cross-Reference

Each sibling tracker follows the same WAT methodology, per-cell confidence tagging, and inline source citation discipline.

24. Sources

The primary sources cited in this tracker are listed below in order of reference. Confidence ratings are reproduced for sponsor citations.

1. USRDS 2024 Annual Data Report, NIDDK.
2. AJKD summary of USRDS 2024 ADR.
3. NIDDK kidney disease statistics.
4. DaVita Inc. Form 10-K, fiscal year ended December 31, 2025.
5. DaVita Inc. Q4 2025 earnings release.
6. Fresenius Medical Care 2025 Annual Report.
7. Matthews dialysis centers 2025 market update.
8. Managed Healthcare Executive dialysis concentration coverage.
9. PMC dialysis concentration peer-reviewed analysis.
10. Dialysis Clinic Inc. Foundation Division.
11. Satellite Healthcare GuideStar profile.
12. Satellite WellBound homedialysis.org listing.
13. CMS CY2026 ESRD PPS Final Rule fact sheet.
14. Federal Register CY2026 ESRD PPS rule.
15. Applied Policy CY2026 ESRD PPS final rule summary.
16. Missouri Hospital Association CY2026 ESRD PPS update.
17. CMS ETC Model page.
18. CMS ETC third evaluation report.
19. Congressional Research Service R45290 on ESRD Medicare coverage.
20. JAMA Network Open ESRD MA enrollment study.
21. PMC PMC11393715 21st Century Cures ESRD MA analysis.
22. Berkshire Hathaway DaVita 8-K share-buyback agreement disclosure.
23. AInvest Buffett DaVita trim analysis.
24. Stockcircle Buffett DaVita transactions log.
25. Benzinga Berkshire DaVita July 2025 sale coverage.
26. Stocktwits Berkshire DaVita pre-Q2 trimming.
27. Investing.com Berkshire February 2025 DaVita sale.
28. DaVita Integrated Kidney Care overview.
29. DaVita Integrated Kidney Care site.
30. DaVita CKCC March 2026 release.
31. DaVita CKCC Northern California regional page.
32. Fresenius Medical Care advances FME Reignite strategy release.
33. PR Newswire FME Reignite launch.
34. Sahm Capital FME Interwell EUR 312M coverage.
35. Bain Capital US Renal Care acquisition release.
36. Healio US Renal Care 2019 acquisition coverage.
37. Dallas Innovates US Renal Care $328M capital raise.
38. Nautic Partners American Renal Associates agreement.
39. BusinessWire ARA Innovative Renal Care completion.
40. Dialyze Direct home page.
41. Dialyze Direct news January 2025.
42. Strive Health Series C release.
43. Strive Central KCE page.
44. Strive PY2022 per-beneficiary savings release.
45. Fierce Healthcare Strive Series D coverage.
46. MedCity News Strive Series D funding.
47. BusinessWire Strive-NANI partnership.
48. BusinessWire Somatus Series E.
49. Fierce Healthcare Somatus Series E coverage.
50. Somatus-Anthem collaboration release.
51. Healthcare Finance News Anthem Somatus partnership.
52. Monogram Health $375M growth release.
53. Fierce Healthcare Monogram Health $375M coverage.
54. Cigna Ventures Monogram Health release.
55. TPG Monogram Series B release.
56. Humana Monogram February 2025 expansion release.
57. PR Newswire Rubicon Founders Evergreen launch release.
58. Rubicon Founders Evergreen portfolio page.
59. PR Newswire Evergreen $130M January 2025 release.
60. Humana Evergreen 2024 specialized care release.
61. Evergreen PY2024 KCC results release.
62. Audax Private Equity Panoramic Health portfolio page.
63. Tracxn Panoramic Health profile.
64. Panoramic Health KHC Cincinnati release.
65. Panoramic Health Texas expansion release.
66. Houlihan Capital Renal Specialists Houston release.
67. CMS KCC PY2025 participant list.
68. Interwell Health three-way merger release.
69. Fierce Healthcare Interwell $2.4B merger coverage.
70. Valtruis Interwell three-way merger release.
71. Hospitalogy kidney care race coverage.
72. WindRose Health Investors Healthmap Solutions recapitalization release.
73. Healthmap Solutions $100M release.
74. Healthmap Solutions Carium acquisition release.
75. Healthmap Solutions national health plan partnership expansion release.
76. Carrick Capital Renalogic recapitalization release.
77. Accolade Renalogic Trusted Partner Ecosystem release.
78. Renalogic self-funded page.
79. NANI about page.
80. CKCC NANI participant list.
81. Outset Medical Q2 2025 strategic positioning deep-dive.
82. Outset Tablo FDA cybersecurity 510(k) release.
83. Outset Medical SWOT analysis.
84. Cybernews DaVita breach coverage.
85. HIPAA Journal DaVita ransomware analysis.
86. TechTarget DaVita ransomware coverage.
87. Benesch Law CMS KCF termination and CKCC revision alert.
88. Jones Day CMS KCC update.
89. CMS KCC PY2026 participant list.
90. CMS KCC 2nd annual evaluation preview.
91. Healthleaders DaVita acquittal coverage.
92. Law360 DaVita acquittal coverage.
93. Dechert DaVita criminal no-poach release.
94. Fierce Healthcare DaVita acquittal coverage.
95. Healio nephrology workforce shortage coverage.
96. ASN Data nephrologist workforce trends.
97. CJASN US Nephrology Workforce Future article.
98. BLS May 2024 OEWS overview.
99. BLS OEWS tables.
100. FOCUS Investment Banking healthcare EBITDA multiples 2026.
101. FOCUS Investment Banking physician practice M&A multiples.
102. Physician Growth Partners nephrology PE Winter 2024 update.
103. CSL Limited tender offer for Vifor Pharma.

25. Frequently Asked Questions

Who owns Evergreen Nephrology?

Rubicon Founders, Oak HC/FT, and K2 HealthVentures, with the January 2025 $130 million round led by Rubicon Founders and Oak HC/FT and K2 HealthVentures joining as a new investor (Evergreen release). KKR is not a sponsor.

Who owns Panoramic Health?

Audax Group, per Audax’s own portfolio page (Audax page). Charlesbank Capital Partners is not a sponsor of record.

Who owns Healthmap Solutions?

WindRose Health Investors since the 2019 recapitalization, with strategic syndicate participation from GuideWell, Highmark Ventures, Shulman Ventures, and Diamond Castle Holdings (WindRose release). Optum is not an owner.

What happened to Cricket Health?

Cricket Health was absorbed into Interwell Health in the August 24, 2022 three-way merger of InterWell Health, Cricket Health, and Fresenius Health Partners at a $2.4 billion valuation (Interwell merger release). It was not acquired by Optum.

Is there an Anthem-Strive joint venture?

No publicly documented Anthem-Strive JV exists. The Anthem CKD-platform pairing of record is Anthem-Somatus, a multi-year capitation agreement covering CKD Stage 3, 4, 5, and ESKD nationally for Anthem-affiliated Medicare Advantage members (Somatus release).

What is the CY2026 ESRD PPS base rate?

$281.71 per treatment, a 2.2 percent increase over CY2025’s $273.82, effective January 1, 2026 (CMS CY2026 fact sheet).

When does the ETC Model terminate?

December 31, 2025, per CMS finalization in the CY2026 ESRD PPS rule (CMS ETC page).

When does the Kidney Care First option terminate?

December 31, 2025, with the PY2026 CKCC reshape replacing KCF (Benesch alert).

How big was the DaVita 2025 ransomware breach?

2,689,826 individuals affected; $13.5 million in Q2 2025 charges; discovered April 12, 2025; initial access March 24, 2025; attributed to the Interlock ransomware group (HIPAA Journal).

What was the Fresenius Interwell Health September 2025 transaction?

Fresenius Medical Care invested EUR 312 million to buy out all non-physician investors in Interwell Health, materially increasing FME’s ownership ahead of the FME25+ cost-savings program (FME release).

What was the Strive Health Series D?

$550 million in September 2025 ($300 million equity Series D plus $250 million debt) at a $1.8 billion valuation, NEA-led with CVS Health Ventures, CapitalG, BlackRock-affiliated funds, Echo, Town Hall, and Redpoint (MedCity News).

How did the DOJ DaVita matter end?

By jury acquittal on April 15, 2022 in the District of Colorado on all three counts of no-poach conspiracy (Dechert release). There is no public record of a separate October 2024 DPA dismissal.

How concentrated is the US dialysis market?

Approximately 80 percent of US dialysis facilities are operated by DaVita or Fresenius Medical Care, with individual US market shares of roughly 37 and 38 percent respectively, making dialysis the most concentrated industry in healthcare per a 2025 peer-reviewed analysis (PMC analysis).

What is the US ESRD population?

More than 808,000 Americans live with ESRD, with 68 percent on dialysis and 32 percent with a functioning kidney transplant (USRDS 2024 ADR).

What share of US dialysis patients are treated at home?

Approximately 2 percent of US dialysis patients are currently treated at home, against an upper-bound clinical addressable share approaching 50 percent (Outset Q2 2025 analysis).

26. Closing Implications for PE Sponsors

Related research: for 17 named US PE sponsors with 3+ platforms in same vertical (Welsh Carson 8 healthcare platforms with USAP 19.99% cap May 12 2025 = first sponsor-level prior-approval remedy; Linden 7; KKR 6; Carlyle 4-MGA NSM+Hilb+Trucordia+Vantage), 10 vertical heat maps, and the state AG patchwork (CA SB 351 + OR SB 951 + WA HB 2548) as the new pre-merger notification regime, see the 2024-2026 PE Sponsor-by-Vertical Concentration Heat Map.

Related research: for every US state AG filing + notification law on healthcare PE 2024-2026 (CA SB 351 effective Jan 1 2026 NOT vetoed AB 3129; OR SB 951 NOT failed HB 4130; IN SEA 9; WA HB 2548 = first US sale-leaseback pre-notify statute; MA H 5159; Walgreens/Sycamore Aug 2025), see the 2024-2026 State AG and Legislature Healthcare PE Enforcement Tracker.

Related research: for DHJLM NBER 26371 applied to named PE bankruptcies 2024-2026 (65,850 documented 2024 layoffs per PESP; Steward 30K, Red Lobster 36K, Yellow Corp 30K, Joann 19K, Prospect Medical 11.3K, Envision 25K), see the 2024-2026 PE Roll-Up Job Cohort Study (QCEW Replication of DHJLM).

The 2024 to 2026 US dialysis and renal disease MSO landscape produces a clear sponsor playbook. First, the value-based CKD platform layer is the structural growth segment; sponsors with healthcare-services depth (Audax via Panoramic, NEA via Strive, Wellington via Somatus, Rubicon plus Oak HC/FT plus K2 via Evergreen, TPG plus Norwest via Monogram, WindRose via Healthmap) hold defensible positions with multi-year MA payor contracts as the primary moat. Second, the in-center duopoly is mature with declining volume, mechanical Berkshire trimming at DaVita, and FME’s pivot to a value-based-plus-Care-Enablement strategy under Reignite; the duopoly is unlikely to produce sponsor returns at the platform level absent a take-private of one of the two public operators, which is constrained by Berkshire’s DaVita stake and by FME’s German parent structure. Third, independent in-center platforms (US Renal Care, Innovative Renal Care) sit at seven-year holding periods with no public exit announced and are likely candidates for sponsor-to-sponsor transactions in 2026 or 2027.

For lower-middle-market sponsors evaluating sub-$5 million EBITDA nephrology MSO add-ons, the seller-fit matrix in Section 21 maps the most likely buyer archetype by seller profile. The default buyer for a small nephrology practice with ancillary contribution is Panoramic Health (Audax); for a multi-site MSO with CKCC participation, the buyer is one of Strive, Somatus, Monogram, Evergreen, or Interwell; for a regional in-center chain, the buyer is US Renal Care, DaVita IKC (consolidation), or Innovative Renal Care. The expected multiple bands range from 4x to 9x EBITDA at the small end to 9x to 14x at the platform end, with value-based platforms commanding strategic premiums beyond the standard MSO bands.

For LPs evaluating fund commitments with exposure to the kidney care vertical, the sponsor diligence emphasis should fall on (a) value-based platform underwriting discipline against CKCC reshape risk, (b) CMS policy risk-corridor underwriting, (c) cyber-incident exposure and insurance adequacy, (d) physician-investor partnership structure (especially for Interwell post-FME consolidation where physicians remain as the residual non-controlling stakeholders), and (e) MA payor contract concentration. Funds with depth across the named sponsor relationships (Bain Capital, Audax, Nautic, Wellington, NEA, Rubicon Founders, Oak HC/FT, WindRose, TPG, Carrick) provide the highest co-investment access to platform-level transactions in the cycle.

The macro takeaway: dialysis is the most concentrated industry in healthcare, with statistically observable commercial pricing power that funds the duopoly’s pivot to value-based care; the value-based CKD layer is the segment where PE returns are made in 2024 through 2026; the Fresenius Interwell consolidation is the strategic signal that vertical integration of in-center and capitation economics is the winning architecture for the cycle; CMS policy risk is permanent and recurring, with CY2026 ESRD PPS, ETC termination, KCF termination, and CKCC reshape all hitting in the same payment year. PE sponsors entering the vertical need depth on both the operating model and the regulatory architecture to underwrite multi-year holding periods with confidence.

27. About the Author

CT Acquisitions is an independent private equity research and acquisitions firm tracking platform-level roll-up activity across US healthcare services verticals. The Wave 7 healthcare PE tracker cohort follows the same WAT (Workflows, Agents, Tools) research methodology, with each tracker tied to primary disclosures and per-cell confidence ratings. Author contact: research at ctacquisitions dot com. This tracker was compiled June 20, 2026 by the CT Acquisitions research team.

Last updated: June 20, 2026.